Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
08:00am, Tuesday, 25'th Feb 2025
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnership
08:52am, Friday, 21'st Feb 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a new agreement with Renaissance Lakewood LLC to advance the development of its lead therapeutic candidate intranasal foralumab. The partnership
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
08:00am, Friday, 21'st Feb 2025
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences announces dosing of additional patients in MS Expanded Access Program
09:43am, Tuesday, 18'th Feb 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that additional patients with non-active secondary progressive multiple sclerosis (na-SPMS) have been dosed with its investigational therapy intranasa
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
08:00am, Tuesday, 18'th Feb 2025
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences says foralumab shows promise in Alzheimer's treatment
12:34pm, Tuesday, 11'th Feb 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational drug, intranasal foralumab, is gaining attention for its potential to address Alzheimer's disease, a condition with limited treatment o
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease
09:15am, Tuesday, 11'th Feb 2025
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injury
03:31pm, Thursday, 23'rd Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced positive results from studies of a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). SCI represents a major global health
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
03:00pm, Thursday, 23'rd Jan 2025
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
08:54am, Thursday, 23'rd Jan 2025
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumab
04:36pm, Wednesday, 22'nd Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with its novel thera
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
04:05pm, Wednesday, 22'nd Jan 2025
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonists
10:09am, Friday, 10'th Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinua
Tiziana Life Sciences welcomes publication of article highlighting foralumab's potential in neurological diseases
08:45am, Wednesday, 08'th Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a review article in Nature Reviews Neurology that examines the potential of its lead therapeutic candidate intranasal foralumab
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
